The relevance of a soluble fibre dietary supplement in cardiovascular disease risk management of patients affected by metabolic syndrome (MS): a 1-year, open-label, randomized clinical trial

Dietary Supplement ◽

Disease Risk ◽

Open Label ◽

Soluble Fibre

Effects of Avena nuda L. on metabolic control and cardiovascular disease risk among Chinese patients with diabetes and meeting metabolic syndrome criteria: secondary analysis of a randomized clinical trial

European Journal of Clinical Nutrition ◽

10.1038/ejcn.2013.201 ◽

2013 ◽

Vol 67 (12) ◽

pp. 1291-1297 ◽

Cited By ~ 19

Author(s):

X Ma ◽

J Gu ◽

Z Zhang ◽

L Jing ◽

M Xu ◽

...

Keyword(s):

Cardiovascular Disease ◽

Metabolic Syndrome ◽

Clinical Trial ◽

Disease Risk ◽

Secondary Analysis ◽

Chinese Patients ◽

Patients With Diabetes ◽

Avena Nuda

Moderate carbohydrate, moderate protein weight loss diet reduces cardiovascular disease risk compared to high carbohydrate, low protein diet in obese adults: A randomized clinical trial

Nutrition & Metabolism ◽

10.1186/1743-7075-5-30 ◽

2008 ◽

Vol 5 (1) ◽

pp. 30 ◽

Cited By ~ 35

Author(s):

Denise Lasker ◽

Ellen M Evans ◽

Donald K Layman

Keyword(s):

Cardiovascular Disease ◽

Clinical Trial ◽

Weight Loss ◽

Disease Risk ◽

Protein Diet ◽

Obese Adults ◽

High Carbohydrate ◽

Low Protein

A randomized clinical trial to determine the efficacy of manufacturers’ recommended doses of omega-3 fatty acids from different sources in facilitating cardiovascular disease risk reduction

Lipids in Health and Disease ◽

10.1186/1476-511x-13-99 ◽

2014 ◽

Vol 13 (1) ◽

Cited By ~ 35

Author(s):

Maggie Laidlaw ◽

Carla A Cockerline ◽

William J Rowe

Keyword(s):

Cardiovascular Disease ◽

Clinical Trial ◽

Fatty Acids ◽

Risk Reduction ◽

Disease Risk ◽

Omega 3 Fatty Acids ◽

Omega 3 ◽

Different Sources

Global Cardiovascular Disease Risk Management in Italian Patients with Metabolic Syndrome in the Clinical Practice Setting

High Blood Pressure & Cardiovascular Prevention ◽

10.2165/00151642-200815020-00001 ◽

2008 ◽

Vol 15 (2) ◽

pp. 37-45 ◽

Cited By ~ 1

Author(s):

Ettore Ambrosioni ◽

Arrigo F G Cicero ◽

Damiano Parretti ◽

Alessandro Filippi ◽

Alessandro Rossi ◽

...

Keyword(s):

Cardiovascular Disease ◽

Metabolic Syndrome ◽

Risk Management ◽

Clinical Practice ◽

Disease Risk ◽

Practice Setting ◽

Clinical Practice Setting

Effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular disease risk factors: a randomized clinical trial

Metabolism ◽

10.1016/j.metabol.2016.07.010 ◽

2016 ◽

Vol 65 (11) ◽

pp. 1636-1645 ◽

Cited By ~ 29

Author(s):

Ivor B. Asztalos ◽

Joi A. Gleason ◽

Sakine Sever ◽

Reyhan Gedik ◽

Bela F. Asztalos ◽

...

Keyword(s):

Risk Factors ◽

Cardiovascular Disease ◽

Clinical Trial ◽

Docosahexaenoic Acid ◽

Eicosapentaenoic Acid ◽

Disease Risk ◽

Cardiovascular Disease Risk Factors

We-P14:482 Efficacy of soluble fiber supplementation in CV disease risk management of patients with metabolic syndrome: A 6-months, randomized clinical trial

Atherosclerosis Supplements ◽

10.1016/s1567-5688(06)81834-9 ◽

2006 ◽

Vol 7 (3) ◽

pp. 453

Author(s):

A.F.G. Cicero ◽

G. Derosa ◽

M. Bove ◽

L. Laghi ◽

A.V. Gaddi

Keyword(s):

Metabolic Syndrome ◽

Clinical Trial ◽

Risk Management ◽

Disease Risk ◽

Soluble Fiber ◽

Cv Disease

The effect of 1-year mean step count on the change in the atherosclerotic cardiovascular disease risk calculation in patients with high cardiovascular risk: a sub-study of the LIGHT randomized clinical trial

Kardiologia Polska ◽

10.33963/kp.a2021.0108 ◽

2021 ◽

Vol 79 (10) ◽

pp. 1140-1142

Author(s):

Mert İlker Hayıroğlu ◽

Tufan Çınar ◽

Göksel Çinier ◽

Arif Karakaya ◽

Muhammet Yıldırım ◽

...

Keyword(s):

Cardiovascular Disease ◽

Clinical Trial ◽

Cardiovascular Risk ◽

Disease Risk ◽

Atherosclerotic Cardiovascular Disease Risk

Atherosclerotic Cardiovascular Disease ◽

High Cardiovascular Risk ◽

Risk Calculation ◽

A randomized clinical trial to determine the efficacy of manufacturers’ recommended doses of omega‐3 fatty acids from different sources in facilitating cardiovascular disease risk reduction (LB329)

The FASEB Journal ◽

10.1096/fasebj.28.1_supplement.lb329 ◽

2014 ◽

Vol 28 (S1) ◽

Author(s):

Maggie Laidlaw ◽

Carla Cockerline ◽

William Rowe

Keyword(s):

Cardiovascular Disease ◽

Clinical Trial ◽

Fatty Acids ◽

Risk Reduction ◽

Disease Risk ◽

Omega 3 Fatty Acids ◽

Omega 3 ◽

Different Sources

Effect of combined lipid-lowering and antioxidant nutraceutical on plasma lipids, endothelial function, and estimated cardiovascular disease risk in moderately hypercholesterolemic patients: a double-blind, placebo-controlled randomized clinical trial

Archives of Medical Science - Atherosclerotic Diseases ◽

10.5114/amsad.2021.107843 ◽

2021 ◽

Vol 6 (1) ◽

pp. 145-151

Author(s):

Arrigo F.G. Cicero ◽

Marilisa Bove ◽

Raffaele I. Cincione ◽

Federica Fogacci ◽

Maddalena Veronesi

Keyword(s):

Cardiovascular Disease ◽

Clinical Trial ◽

Endothelial Function ◽

Plasma Lipids ◽

Disease Risk ◽

Lipid Lowering ◽

Double Blind ◽

Double Blind Placebo

General practitioners maintain a focus on blood pressure management rather than absolute cardiovascular disease risk management

Journal of Evaluation in Clinical Practice ◽

10.1111/jep.13569 ◽

2021 ◽

Author(s):

Niamh Chapman ◽

Rebekah E. McWhirter ◽

Kim A. Jose ◽

Martin G. Schultz ◽

Douglas Ezzy ◽

...

Keyword(s):

Blood Pressure ◽

Cardiovascular Disease ◽

Risk Management ◽

General Practitioners ◽

Disease Risk ◽

Pressure Management ◽

Blood Pressure Management